Photo by mykjohnson from unsplash
A ≥50% subjective improvement in urinary symptoms during sacral neuromodulation testing (SNM‐I) is currently used as the indication for progression to second‐stage implantation (SNM‐II). While most patients will have successful… Click to show full abstract
A ≥50% subjective improvement in urinary symptoms during sacral neuromodulation testing (SNM‐I) is currently used as the indication for progression to second‐stage implantation (SNM‐II). While most patients will have successful SNM‐I and proceed to SNM‐II, deterioration in efficacy over time has been reported. It remains unclear if the durability of efficacy is related to the initial symptom reduction. We sought to determine if the degree of improvement after SNM‐I is sufficient to predict long‐term success.
Journal Title: Neurourology and Urodynamics
Year Published: 2021
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!